Drug Type Gene therapy |
Synonyms AAV-MYO7A (AAVantgarde Bio) |
Target |
Mechanism MYO7A modulators(myosin VIIA modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization AAVantgarde Bio SrlStartup |
Active Organization AAVantgarde Bio SrlStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Usher Syndrome, Type 1B | Preclinical | IT | AAVantgarde Bio SrlStartup | 11 Jul 2024 |